



The Canadian Association for Population Therapeutics presents:

**“Effectiveness and Safety of Therapeutics:
Dealing with Transparency, Minimizing Bias, and
Improving Knowledge Translation to Concerned
Stakeholders”**

PROGRAM

**May 6th – 8th, 2012
Montreal, Quebec
Hyatt Regency Montreal**

CAPT MISSION & VISION

The CAPT Mission is to advance population-based research of therapeutic interventions to improve the health outcomes of Canadians by:

- Bringing together diverse perspectives
- Facilitating open exchange of ideas and collaboration, and
- Influencing policy and practice

The CAPT Vision is to become the recognized Canadian leader for linking population-based therapeutic research, policy and practice to optimize health outcomes.

CAPT 2012 SCIENTIFIC PROGRAM COMMITTEE:

Anick Bérard (Chair), University of Montreal
Farah Jivraj, sanofi-aventis Canada
Nicole Mittmann, HOPE Research Centre
Corine Mizrahi, CNODES
Wendy Morton, Merck Canada
Elham Rahme, McGill University
Angela Rocchi, Axia Research

CAPT 2012 LOCAL ORGANIZING COMMITTEE:

Odile Sheehy (Chair), CHU Ste-Justine
Allan Gillman, IMS Brogan

“Effectiveness and safety of therapeutics: Dealing with transparency, minimizing bias, and improving knowledge translation to concerned stakeholders”

Message from the President

Welcome to the 2012 Canadian Association for Population Therapeutics (CAPT)/ Association Canadienne pour la Thérapeutique des Populations (ACTP) annual conference! We are pleased to be in Montreal this year to address drug safety and effectiveness from the perspectives of academia, industry and government, which makes CAPT distinct from other organisations.

Again this year, CAPT will be hosting extremely relevant symposiums, abstract sessions, a student event as well as a social event at the Musée d'Art Contemporain de Montréal. This year, an abstract session will be specifically dedicated to studies on safety and effectiveness. On behalf of the board of CAPT, we hope you enjoy the conference and look forward to the next few days of learning, discussing and networking with colleagues.

Anick Bérard
CAPT President

CAPT 2012 Conference Overview

Welcome to the 2012 CAPT/ACTP conference! The title of this year's conference, 'Effectiveness and safety of therapeutics: Dealing with transparency, minimizing bias, and improving knowledge translation to concerned stakeholders', speaks to the need for good quality studies on drug safety and effectiveness in order to improve and increase knowledge translation and policy making. The Scientific Program Committee offers its sincere thanks to the sponsors who have made this conference possible.

The mission of CAPT/ACTP is to advance population-based research of therapeutic interventions to improve the health of Canadians by bringing together diverse perspectives, facilitating open exchange of ideas and collaboration, and influencing policy and practice. The Scientific Committee has designed the conference program to achieve this mission by inviting a wide variety of keynote speakers and panelists from all CAPT constituencies. This year for the first time, an advanced course on pharmacoeconomics will be offered. Finally, we have many exciting contributed presentations and posters. We encourage you to maximize your opportunities for interaction and exchange of ideas throughout the three days with both old and new colleagues and friends, and hope that you enjoy the conference.

Anick Bérard & Odile Sheehy
2012 Scientific and Planning Committee

“Effectiveness and safety of therapeutics: Dealing with transparency, minimizing bias, and improving knowledge translation to concerned stakeholders”

Sunday, May 6, 2012

07:15 – 17:00 Registration (Soprano Foyer)

Pre-Conference Symposium

Location: Soprano A&B

Chair: Fabiano Santos, McGill University

08:00 – 10:00 Introduction to Pharmacoepidemiology
Anaïs Lacasse, University of Quebec in Abitibi

Demystifying Private Drug Plans
Suzanne Lepage, Suzanne Lepage Consulting

10:00 – 10:30 Coffee Break (Soprano Foyer)

10:30 – 12:00 Advanced Pharmacoeconomics : The QALY - Pros and Cons
Jean Lachaine, University of Montreal

12:00 – 13:00 Welcome Lunch (Sponsored by: Novartis Pharmaceuticals)
(All conference registrants welcome)
Location: Soprano Foyer

Conference Commencement

Location: Soprano A&B

13:00 – 13:15 Opening Remarks & Welcome
Anick Bérard, University of Montreal and President, CAPT

Issues Panel

Location: Soprano A&B

Sponsored by: Janssen

Sunday, May 6, 2012

Biomarkers and Surrogate Outcomes: Linking Relevance, Regulation, and Reimbursement in Canada

Chair: Mitchell Levine, McMaster University

13:15 – 13:30	Introductory Remarks
	Mitchell Levine, McMaster University
13:30 – 13:55	Clinical Trials and Clinical Practice: Surrogates at the Clinician/Patient Interface
	Linda Lévesque, Queen University
13:55 – 14:20	The Regulatory Perspective on Surrogates
	Agnes Klein, Health Canada
14:20 – 14:45	The Impact of Surrogates in Reimbursement Recommendations
	Angela Rocchi, Axia Research
14:45 – 15:15	Panel / Plenary Discussion
15:15 – 15:45	Break & Contributed Poster Presentations Location: Soprano C & Soprano Foyer

Contributed Oral Presentations

Concurrent Session 1: Pharmacoeconomic and Methodological Issues

Location: Soprano A

Chair: Suzanne Cadarette, University of Toronto

15:45 – 16:00	Disease Risk Scores (DRS) as a Summary Confounder Method: Systematic Review and Recommendations
	Mina Tadrous, University of Toronto
16:00 – 16:15	Economic Benefit of Subcutaneous Rapid Push Versus Intravenous Immunoglobulin Infusion Therapy in Adult Patients with Primary Immune deficiency
	Mireille Goetghebeur, BioMedCom, Montreal

Sunday, May 6, 2012

16:15 – 16:30 **The Impact of the Type of Drug Insurance Plan on Costs of Antidepressants and Statins**
Lucie Blais, University of Montreal

16:30 – 16:45 **Pharmacoeconomic Evaluation of 13-Valent Pneumococcal Conjugate and 23-Valent Pneumococcal Polysaccharide Vaccine in Canadian Adults**
Andy W. Chuck, Institute of Health Economics

16:45 – 17:00 **Relative Generic Usage and Drug Expenditures After Branded Patent Expiry: Not a Quick Enough Switch**
Dahlia Balaban, University of Toronto

17:00 – 17:15 **Treatment with Rivastigmine or Galantamine and Hospitalization for an Adverse Cardiac Event: a Dutch Database Study**
Edeltraut Kroger, Centre d'excellence sur le vieillissement de Quebec

Concurrent Session 2: Validity of Exposure and Health Care Professional Involvement in Research

Location: Soprano B

Chair: Robert Platt, McGill University

15:45 – 16:00 **Impact of Exposure Misclassification Due to Incomplete Drug Data in Observational Studies of Safety and Effectiveness: a Cohort Study**
Dean T. Eurich, University of Alberta

16:00 – 16:15 **Pharmacy-Based Research Network: the Perception of Community Pharmacists**
Lyle Lalonde, University of Montreal

16:15 – 16:30 **A Review of Instruments Measuring Patient Attitudes Toward Antidiabetic Drug Therapy**
Hervé Tchala Vignon Zomahoun, Laval University

16:30 – 16:45 **The Effect of Treatment Adherence on Smoking Abstinence in Patients Post-Acute Myocardial Infarction**
Sonia M. Grandi, McGill University

16:45 – 17:00 **Development of a Questionnaire Measuring Psychosocial Determinants of Adherence to Oral Antidiabetic Drug Treatment**
Gabriel Giguère, Laval University

Sunday, May 6, 2012

17:00 – 17:15	Adherence to Antidiabetic Drug Treatment Among Workers with Type 2 diabetes Mohamed Amine Amiche, Laval University
17:15 – 18:15	Reception (Sponsored by: Pfizer Canada) & Contributed Poster Presentations Location: Soprano C and Soprano Foyer
18:00 – 20:00	Student Dinner (open to CAPT student registrants only) Location: Hyatt Regency Bar

Monday, May 7, 2012

07:00 – 17:00	Registration (Soprano Foyer)
07:00 – 08:00	Breakfast (Sponsored by: Astellas Pharma Canada) Location: Soprano Foyer

Keynote Speakers: Dealing with Bias, Maximizing Safety and Accessibility

Location: Soprano A&B

Chair: Anick Bérard, University of Montreal

8:00 – 9:00	Time Related Bias in Pharmacoepidemiology? Samy Suissa, McGill University
9:00 – 10:00	Drug Approval Process in Canada: Finding a Middle Ground Between Accessibility and Safety Nigel Rawson, Eastlake Research Group
10:00 – 10:30	Break & Contributed Poster Presentations

CNODES: Canadian Network for Observational Drug Effect Studies

Location: Soprano A&B

Sponsored by: CIHR / DSEN / CNODES

Chair: Mitchell Levine, McMaster University

10:30 – 10:40	An Introduction to CNODES Samy Suissa, McGill University
----------------------	--

Monday, May 7, 2012

10:40 – 11:00	Statins and Acute Kidney Injury: A National Meta-Analyses of Observational Studies
	Colin Dormuth, University of British Columbia
11:00 – 11:15	Strategies for Distributed Database Analysis
	Michael Paterson, Institute for Clinical Evaluative Sciences
11:15 – 11:30	Proton-Pump Inhibitors and the Risk of Pneumonia: A Clinical Perspective
	Laura E. Targownik, University of Manitoba
11:30 – 11:45	Proton-Pump Inhibitors and the Risk of Hospitalization for Community-Acquired Pneumonia: A National Meta-Analysis of Observational Studies
	Kristian B. Filion, McGill University
11:45 – 12:00	Antipsychotics and Hyperglycemic Emergencies: Study Design
	Lorraine Lipscombe, University of Toronto
12:00 – 12:15	Methodological Challenges for Meta-Analyses of Observational Studies
	Robert Platt, McGill University
12:15 – 12:30	Question & Answer Period
12:30 – 13:30	Lunch (Sponsored by: Takeda Canada) Location: Soprano Foyer
12:45-13:30	CAPT Annual General Meeting Location: Soprano A&B

Engaging Patients and Citizens in HTA Decision Making

Location: Soprano A&B

Sponsored by: sanofi-aventis Canada

Chair: Paul Oh, University Health Network

Monday, May 7, 2012

13:30 – 14:15	A Brokered Dialogue on the Experience of the Citizens Council in Ontario Janet Parsons and Jim Lavery, Li Ka Shing Institute
14:15 – 14:35	Patients and Patient Associations in HTA both Nationally and Internationally Durhane Wong - Reiger, President of CORD
14:35 – 15:00	Perspective as a Decision Maker on the Involvement of Patients and Citizens in HTA Decision Making Gerald Evans, Past CED Chair of Ontario
15:00 – 15:30	Discussion and Question Period
15:30 – 16:00	Break & Contributed Poster Presentations Location: Soprano C & Soprano foyer

Contributed Oral Presentations

Concurrent Session 1: Drug Safety and Effectiveness Studies

Location: Soprano A

Sponsored by: CIHR / DSEN

Chair: Lucie Blais, University of Montreal

16:00 – 16:15	Survival with Adherence to Beta-Blocker Medications in Heart Failure: The 'Unhealthy- Adherer' Effect? Wasem Alsabbagh, University of Saskatchewan
16:15 – 16:30	Cost-effectiveness of Intravenous Thrombolysis Compared to Best Medical Treatment for Late-Presentation Acute Ischemic Stroke in an Ontario Setting Julian Nam, McMaster University
16:30 – 16:45	Variation in the Days Supply Field for Osteoporosis Medications in Ontario Andrea M Burden, University of Toronto
16:45 – 17:00	Reliability of Exposure to Vaccine Products: Agreement Between Patients' Self-Report and Medical Records in the PGRx Database Michel Rossignol, LA-SER

Monday, May 7, 2012

17:00 – 17:15 The Efficacy and Safety of New Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis
Corey S Miller, McGill University

17:15 – 17:30 Metformin Use and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes Mellitus
Brielan S Smiechowski, McGill University

Concurrent Session 2: Chronic Diseases

Location: Soprano B

Chair: Elham Rahme, McGill University

16:00 – 16:15 Description of Drug Utilization in Newly Diagnosed Patients with Pervasive Development Disorder in the Province of Quebec
Caroline Croteau, University of Montreal

16:15 – 16:30 Trends in Post-Traumatic Use of Analgesics and Arthritic-Related Medications Following Lower-Limb Joint Injuries in the Population of the Province of Quebec, Canada
Julie Vaillancourt, McGill University

16:30 – 16:45 Impact of Maternal Attachment on Children Development at 1-Year of Age: Results from the OTIS Antidepressants in Pregnancy Study
Fatiha Karam, University of Montreal

16:45 – 17:00 Beware of Policy-Induced Selection Bias in Drug Effect Studies: Example in the Comparative Effectiveness of Oral Bisphosphonates
Suzanne M Cadarette, University of Toronto

17:00 – 17:15 Are Deep Venous Thrombosis Events Accurately Identified Using Administrative Databases? A Systematic Review
Caroline Sirois, McGill University

17:15 – 17:30 Systematic Follow-Up of Fragility Fractures: Preliminary Results of a Treatment Adherence
Sylvie Perreault, University of Montreal

Monday, May 7, 2012

**18:00 – 20:00 Social Event – “Musée d’Art Contemporain de Montréal”
Dinner Cocktail with 2 free drinks - Open to those with tickets**
Speakers: Lucie Robitaille, Secretary General and Associate General Director of Organizational Development and Medications at INESSS and Diane Lamarre, President, Ordre des pharmaciens du Québec

Tuesday, May 8, 2012

07:30 – 13:00 Registration (Soprano Foyer)

**07:00 – 08:00 Special Interest Group Breakfast: Medications and Pregnancy
Location: Imagination**

**07:00 – 08:00 Breakfast (Sponsored by: GlaxoSmithKline Canada)
Location: Soprano Foyer**

Canada’s Drug Effectiveness and Safety Network’ – How Are Other Jurisdictions Managing Real World Safety and Effectiveness and Are There Lessons for Canada?

Location: Soprano A&B

Sponsored by: Merck Canada

Chair: William Dempster, 3Sixty Public Affairs

**8:00 – 8:20 DSEN’s Experience
Diane Forbes, DSEN**

**8:20 – 8:40 Government Experience
Reiner Banken, INESSS**

**8:40 – 9:00 Pharmaceutical Experience
William Dempster, 3Sixty Public Affairs Inc.**

**9:00 – 9:20 US Experience
Sean Hennessy, University of Pennsylvania**

9:20 – 10:00 Panel / Plenary Discussion

**10:00 – 10:30 Coffee Break
Location: Soprano Foyer**

Tuesday, May 8, 2012

Lost Productivity and Indirect Costs

Location: Soprano A&B

Chair: Nicole Mittmann, HOPE Research Centre

10:30 – 10:55	Use of Productivity Information by Private Plan Decision Makers when Assessing Value of New Medications and Treatments Suzanne Lepage, Suzanne Lepage Consulting
10:55 – 11:20	Work Related Lost Productivity: What is the Economic Impact in Canadians Suffering with Psoriasis? Brian Chan, University of Toronto
11:20 – 11:45	Financial Burden of Cancer on the Caregiver Chris Longo, McMaster University
11:45 – 12:10	Patient Financial Burden from Wage Losses and Out-Of-Pocket Costs in the Year After Early Breast Cancer Sophie Lauzier, Laval University
12:10 – 12:30	Panel Discussion & Questions
12:30-13:00	Lunch (Sponsored by: Amgen Canada) Location: Soprano foyer

Hot Topic Session – Sustainability of the Healthcare System, and Equitable and Timely Access to New Medications – Attainable Goals?

Location: Soprano A&B

Chair: Jacques LeLorier, University of Montreal

13:00 – 13:25	Academic perspective: Aslam Anis, University of British Columbia
13:25 – 13:50	Government perspective: Lucie Robitaille, INESSS
13:50 – 14:15	Industry perspective: Mark Fleming, Janssen
14:15 – 14:40	Patient perspective: Harlon Davey, Committee to Evaluate Drugs
14:40 – 15:00	Discussion
15:00-15:15	CAPT Awards Ceremony / Conference Close Nicole Mittmann, Incoming CAPT President

ORAL PRESENTATIONS

(Note: Presenting Authors are underlined)

1

Zomahoun HTV, Lauzier S, Guenette L, Moisan J **A review of instruments measuring patient attitudes toward antidiabetic drug therapy**

2

Amiche MA, Guenette L, Gregoire JP, Moisan J **Adherence to antidiabetic drug treatment among workers with type 2 diabetes**

3

Sirois C, Rahme E, Avina-Zubieta JA, Bertnatsky S, Lacaille D **Are deep venous thrombosis events accurately identified using administrative databases? A systematic review**

4

Cadarette SM, Levesque L, Mamdani MM, Perreault S, Juurink DN, Paterson JM, Carney G, Gunraj N, Nikitovic M, Hawker GA, Dormuth CR **Beware of policy-induced selection bias in drug effect studies: example in the comparative effectiveness of oral bisphosphonates**

5

Nam J, O'Reilly D **Cost-effectiveness of intravenous thrombolysis compared to best medical treatment for late-presentation acute ischemic stroke in an Ontario setting**

6

Croteau C, Mottron L, Dorais M, Perreault S **Description of drug utilization in newly diagnosed patients with pervasive development disorder in the province of Quebec**

7

Giguere G, Guillaumie L, Lauzier S, Guenette L, Gregoire J-P, Moisan J **Development of a questionnaire measuring psychosocial determinants of adherence to oral antidiabetic drug treatment**

8

Tadrous M, Gagne JJ, Stürmer T, Cadarette SM **Disease Risk Scores (DRS) as a summary confounder method: systematic review and recommendations**

9

Martin A, Lavoie L, Goetghebeur M, Schellenberg R **Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency**

10

Gamble JM, Johnson JA, McAlister FA, Majumdar SR, Simpson SH, Eurich DT **Impact of exposure misclassification due to incomplete drug data in observational studies of safety and effectiveness: a cohort study**

11

Karam F, Sheehy O, Huneau MC, Briggs G, Chambers C, Einarson A, Johnson D, Kao K, Koren G, Martin B, Polifka JE, Riordan SH, Roth M, Voyer Lavigne S, Wolfe L, Bérard A and the OTIS Research Committee **Impact of maternal attachment on children development at 1-year of age: Results from the OTIS Antidepressants in Pregnancy Study**

12

Smiechowski BS, Suissa S, Azoulay L, Yin H, Pollak M **Metformin use and the incidence of colorectal cancer in patients with type 2 diabetes mellitus**

13

Chuck AW, Waye A, Zanotti G, Jacobs P, Tyrrell G, Kellner JD **Pharmacoeconomic evaluation of 13-Valent Pneumococcal Conjugate and 23-Valent Pneumococcal Polysaccharide Vaccine in Canadian Adults**

14

Hebert J, Laliberte MC, Berbiche D, Jouini G, Martin E, Lalonde L **Pharmacy-based research network: the perception of community pharmacists**

15

Balaban DY, Dhalla IA, Bell CM **Relative generic usage and drug expenditures after branded patent expiry: not a quick enough switch**

16

Bensouda-Grimaldi L, Rossignol M, Aubrun E, Leighton P, Bénichou J, Abenaim L and the PGRx Group **Reliability of exposure to vaccine products: Agreement between patients' self-report and medical records in the PGRx database**

17

Alsabbagh MW, Lamb D, Blackburn DF **Survival with adherence to beta-blocker medications in heart failure: the 'Unhealthy-adherer' effect?**

18

Perreault S, Fernandes J, Delisle J, Beaubois C, Beaumont P, Benoit B, Gagnon S, Jodoin A, Laflamme Y, Leduc S, MacThiong JM, Malo M, Maurais G, Parent S, Ranger P, Troyanov Y **Systematic follow-up of fragility fractures : preliminary results of a treatment adherence**

19

Grandi SM, Filion KB, Gervais A, Joseph L, O'Loughlin J, Paradis G, Pilote L, Rinfret S, and Eisenberg MJ for the ZESCA Investigators **The effect of treatment adherence on smoking abstinence in patients post-acute myocardial infarction**

20

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ **The efficacy and safety of new oral anticoagulants versus warfarin in patients with atrial fibrillation: a systematic review and meta-analysis**

21

Blais L, Assayag J, Pare A, Forget A, Kettani FZ **The impact of the type of drug insurance plan on costs of antidepressants and statins**

22

Kroger E, Berkers M, Carmichael PH, Souverein P, van Marum R, Egberts T **Treatment with rivastigmine or galantamine and hospitalization for an adverse cardiac event: a dutch database study**

23

Vaillancourt J, Sampalis JSS **Trends in post-traumatic use of analgesics and arthritic-related medications following lower-limb joint injuries in the population of the province of Quebec, Canada**

24

Burden AM, Huang A, Tadrous M, Cadarette SM **Variation in the days supply field for osteoporosis medications in Ontario**

POSTER PRESENTATIONS

25

Bartlett G, Longo C, Macgibbon B, Mayo N, Daskalopoulou S, Dawes M, Barnett T, Khayyat Kholghi M **A novel knowledge translation approach for addressing the role of obesity in prescribing practices**

26 - ENCORE PRESENTATION

Bernatsky S, Lacaille D, O'Donnell S, Lix L, Bombardier C, and the Administrative Data Rheumatology Research and Surveillance Group **Administrative data in rheumatology research and surveillance: best practices**

27

Lalonde L^{1,2,3}, Choiniere M^{4,5}, Martin E², Haworth C⁶, Bergeron D⁷, De GrandPre P⁸, Hudon E^{2,5}, Gobeil F, Bourgault P, Tousignant-Laflamme Y **AGIR: a self-management program for osteoarthritis patients and primary care clinicians supported by a group of interdisciplinary regional clinicians**

28 - ENCORE PRESENTATION

Diaby V, Lachaine J **An application of a proposed framework for formulary listing in low-income countries: the case of Cote d'Ivoire**

29

Muanda FT, Berard A **Antimalarial drugs and the risk for the pregnant women and fetuses: Review of the literature**

30

Morarescu E, Bouchard S, Beaulieu C **Antipsychotic use in elderly patients with dementia in Quebec, in 2006 and 2009**

31

Gamaoun R, Sheehy O, Berard A **Caffeine intake during pregnancy and the risk of preterm birth**

32

Morgan S, Cunningham C, Law M **Changing scientific and policy paradigms in the pharmaceutical sector: reflections from a program of research conducted in partnership with decision makers**

33

Savoie M **Comparative analysis of interprovincial and international legal framework and modalities for negotiations between public payers and pharmaceutical manufacturers on price and reimbursement of drug products - Proposal of a Conceptual Framework for Quebec**

34

Vicente C, Lynde C, Poulin Y, Sabapathy S, Boisjoly L, Piwko C **Cost-effectiveness of TOCTINO® (Alitretinoin) versus cyclosporine in adult patients with severe chronic hand eczema unresponsive to potent topical corticosteroids**

35

Beaulieu Boivin A, Choiniere M, Martin E, Berbiche D, Perreault S, Lussier D, Lalonde L **Costs of moderate to severe pain in primary care patients - A study of the Programme ACCORD**

36

Quintana-Barcena P, Lord A, Jouini G, Martin E, Beaunoyer S, Dumoulin-Charette A, Dupuis S, Guay M, Ricard S, Lalonde L **Development of a new tool to evaluate the severity of drug-related problems in chronic kidney disease patients**

37

Ma J, Ling N, Polk G **Disparities in access to cancer drugs as a result of provincial government pharmaceutical policies**

38

Chaabane S, Berard A **Epidemiology of major congenital malformations with specific focus on teratogens**

39

Besso A, Mazier P **Fat Consumption in First and Fourth Year University Students**

40

Paterson JM, Mamdani MM, Manno M, Juurlink DJ, and the Canadian Drug Safety and Effectiveness Research Network **Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study**

41 - ENCORE PRESENTATION

Ray W, Bernatsky S, Suisse S, Sylvestre MP, Abrahamowicz M **Glucocorticoid Therapy and Serious Infections in rheumatoid arthritis: a nested case-control study using a weighted cumulative cose model**

42

McCormick N, Marra CA, Colley L, Grubisic M, Sayre EC, Avina-Zubieta JA **Growing prescription drug costs, despite more efficient health care delivery, in cases with systemic autoimmune rheumatic diseases in British Columbia, Canada: a population-based study**

43

Gomes T, Camacho X, Hellings C, Juurlink D, Paterson JM, Laupacis A, Dhalla IA, Mamdani MM **High cost beneficiaries of the Ontario Drug Benefit (ODB) program**

44

Blais L, Kettani F-Z, Forget A **Impact of maternal asthma, its severity and control, on the risk of abortions**

45

Patil DS, Issa AM **Impact of Physician and Technology Factors on the Adoption of Personalized Genomic Diagnostics in Breast Cancer**

46

Zomahoun HTV, Guenette L, Moisan J **Interventions that improve adherence to oral antidiabetic in adults with type 2 diabetes: a systematic review**

47

Nam J, He J, O'Reilly D **Intra-arterial thrombolysis versus standard treatment or intravenous thrombolysis in adults with acute ischemic stroke: a systematic review and meta-analysis**

48

Forte L, Jobin M, Amin M, Boyle L, Richler D **Multi-criteria decision analysis: how does Canada measure up?**

49

Iskedjian M, McLean A, Berbari J, Farah B, Watson JA, Walker J, Gafni A, LeLorier J **No Starting Point Bias with the Bidding Game in a Willingness-to-Pay Analysis**

50

Laliberte MC, Perreault S, Damestoy N, Lalonde L **Perceptions of community pharmacists regarding their involvement in the management of osteoporosis and the risk of falls**

51

Vaillancourt J, Sampalis JSS **Post-traumatic use and cost of analgesics and arthritic-related medications following lower-limb joint injuries in the population of the province of Quebec, Canada**

52

Gamaoun R, Sheehy O, Berard A **Predictors of caffeine intake during pregnancy**

53

Mittmann N, Seung SJ, Hassan S, Bannon G, Craven BC **Preliminary results from the baseline questionnaire of the burden of bowel dysfunction in spinal cord injury study**

54

Beaulieu S, Bertin E, Bouvrette M, Daigneault AM, El Bouchikhi M, Forget R, Noel I, Bell R, Lord A, Jouini G, Martin E, Lalonde L **Programme ProFil - A training-and-communication network program in nephrology: an interim analysis**

55

Iskedjian M, Navarro V, Berbari J, LeLorier J **Systematic review of the literature on starting point bias in the bidding games of willingness-to-pay analyses**

56

Consiglio GP, Cadarette SM **Systematic review of the case-crossover design in pharmacoepidemiology**

57

Breton MC, Guenette L, Amiche MA, Kayibanda JF MA, Gregoire JP, Moisan J **The burden of type 2 diabetes on work productivity: a systematic review**

58 - ENCORE PRESENTATION

Filion KB, Grandi SM, Joseph L, O'Loughlin J, Paradis G, Pilote L, Rinfret S, Eisenberg MJ, and the ZESCA Investigators **The effect of bupropion on symptoms of depression among patients attempting to quit smoking post-myocardial infarction: The ZESCA Trial**

59

Eltonsy S, Kettani FZ, Blais L **The effect of SABA and LABA on fetal development and prematurity among asthmatic women: An updated**

60

Sheehy O, De Vera M, Kermarrec M, Blais L, Rahme E, Perreault S, Moisan J, Berard A **The impact of unmeasured confounders in cardiovascular studies performed in administrative databases**

61

Wu CQ, Grandi SM, Filion KB, Abenhaim HA, Joseph L, Eisenberg MJ **The Risk of Venous Thromboembolism of Drospirenone-Containing Combined Oral Contraceptives: A Systematic Review and Meta-Analysis**

62

Laliberte MC, Perreault S, Damestoy N, Lalonde L **The role of community pharmacists in health promotion and prevention: a cross-sectional study**

63

El-Hadi W, Dorais M, Raymond V **Thromboprophylaxis patterns in patients undergoing elective total knee and hip replacement surgery in the province of Quebec**

64

Lalonde L, Goudreau, J, Hudon E, Duhamel F, Lussier MT, Bareil C, Levesque L, Ladouceur M, Poirier N, Milard A **TRANSIT: a primary care interprofessional intervention program to improve the management of cardiovascular risk factors in patients with multiple chronic conditions**

65

Richard-Tremblay AA, Sheehy O, Berard A **Trends in dispensations of high dose folic acid and birth prevalence of major congenital malformations**

66

Gillman AF **Using Anonymized Longitudinal Patient Data to Monitor the Impact of Formulary Differences on Patient Treatment when Transitioning from Private to Public Coverage in Canada**

67

Blais L, Berard A, Kettani FZ, Forget A **Validation of congenital malformation diagnostic codes recorded in Quebec administrative databases**

68

Guenette L, Breton MC, Gregoire JP, Moisan J **Vascular protection with ACE inhibitors or angiotensin II receptor antagonists following type 2 diabetes treatment initiation in elderly**

69

Rawson NSB **When the Risk of Confounding by Indication is High, Are Administrative Data Adequate to Achieve Scientific Excellence in Pharmacoepidemiology?**



2012 CAPT / ACTP CONFERENCE SPONSORS

PLATINUM

DSEN / CHIR (logo)
Janssen (logo)
Merck Canada (logo)
sanofi-aventis Canada (logo)

GOLD

Amgen Canada (logo)
Astellas Pharma Canada (logo)
CNODES / CIHR (logo)
GlaxoSmithKline (logo)
Novartis Pharmaceuticals (logo)
Pfizer Canada (logo)
Takeda Canada (logo)

SILVER

Axia Research (logo)
Bayer Canada (logo)
Canada's Research-Based Pharmaceutical Compagnies (Rx&D) (logo)
LA-SER (logo)
OptumInsight Life Sciences (logo)
Purdue Pharma (logo)
StatSciences (logo)
Union Chimique Belge (UCB) (logo)

BRONZE

Cornerstone Research (logo)
HOPE Research Centre (logo)
Institute of Health Economics (logo)
Oxford Outcomes (logo)
Servier Canada (logo)